[ad_1]
LAS VEGAS, Nevada, Sept. 30, 2022 (GLOBE NEWSWIRE) — Odyssey Health, Inc. He decided to disband the Sports Advisory Board over developing a special drug to treat concussions.
The Sports Advisory Board members advocate for the importance of concussion prevention and responsible access to treatment. We created the advisory board to increase awareness of our mission to bring much-needed pharmaceuticals to a condition that currently has no FDA-approved treatment. We recently completed a phase 1 human trial in which our drug was proven to be safe and well-tolerated. We are excited about the potential of starting a Phase II trial to determine the drug’s efficacy and safety in depressed patients.
The Press Odyssey Health, Inc. Odyssey has never received funding directly or indirectly from state or federal government sources for drug development. Odyssey is not involved in any litigation. Odyssey Health, Inc. He purchased the intellectual property and rights to the drug on March 1, 2021. Funding for drug development comes from accredited investors. The company contacted the press to advise on the facts and misconceptions.
The organization decided to disband the Sports Advisory Board as it created a distraction from the important work being done to keep us focused. Odyssey wants to continue to focus on this important drug candidate in hopes of providing a much-needed treatment. The company is committed to bringing products to market that address unmet medical needs.
About Odyssey Health Inc. (Formerly Odyssey Group International, Inc.)
Odyssey Health Inc. (OTC: ODYY) is a medical company focused on lifesaving medical solutions. Odyssey’s corporate mission is to create, acquire and develop unique assets, intellectual property and unique technologies that deliver meaningful medical solutions. The company is focused on areas with distinct technological advantage, superior clinical service delivery and broad market opportunity. For more information, visit the company’s website at www.odysseyhealthinc.com.
About PRV-002
PRV-002 is a fully synthetic, non-naturally occurring neurosteroid developed for the treatment of mTBI (concussive concussion). In preclinical studies, PRV-002 has demonstrated comparable, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion have shown that PRV-002 reduces behavioral pathology associated with symptoms of brain damage, such as memory impairment, anxiety, and motor/sensory deficits. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier and rapidly remove inflammation, oxidative stress and inflammation in the brain and restore proper blood flow.
Forward-looking statements
This news release The Private Securities Litigation Amendment Act of 1995 may contain forward-looking statements within the meaning of the “safe harbor” provisions. Such statements are based on our current expectations and speak only as of this date.
Questions:
Odyssey health
info@odysseyhealthinc.com
[ad_2]
Source link
